

Andrea L. Kasinski

Associate Professor with tenure; Department of Biological Sciences; Purdue Center for Cancer Research, Purdue University, Hansen Life Sciences Research Building, Room B054C, West Lafayette, Indiana 47907; Ph. (765) 496-1658; E-mail: akasinski@purdue.edu

Lab Website: <https://www.bio.purdue.edu/lab/kasinski/>
LinkedIn: <http://www.linkedin.com/pub/andrea-kasinski/2a/43b/34a>
ResearcherID E-7951-2014: <http://www.researcherid.com/>
Complete List of Published Work in My Bibliography:
<https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/46436535/?sort=date&direction=>

Education

- Ph.D.** [2009] Emory University. Area: Genetics and Molecular Biology. August 2009
B.A. [1996] State University of New York College at Buffalo. Major, Mathematics & Biology

Research and Professional Appointments

Purdue University

- 2022 – pres. Program Leader, Purdue Center for Cancer Research
2021 – pres. Chair of Graduate Program in Biological Sciences, Purdue University
2020 – pres. Associate Professor with Tenure, Biological Sciences, Purdue University
2013 – 2020 William and Patty Miller Assistant Professor, Biological Sciences, Purdue University

Yale University

- 2009 – 2013 Postdoctoral Fellow, New Haven CT, (Dr. Frank J. Slack)

Sacred Heart University

- 2010 – 2013 Adjunct Lecturer, Fairfield CT

Post University

- 2010 – 2010 Adjunct Lecturer, Waterbury CT

Emory University

- 2003 – 2009 Ph.D. Candidate, Atlanta GA, (Dr. Haiyan Fu)

Awards and Honors

- 2023 American Association for Cancer Research, Plenary Speaker invitation for annual meeting
2022 Bio Crossroads, 23 PAIR Fellow – Recognizing the next generation of Indiana’s life sciences talent
2022 Recipient of Department of Defense, Idea Development Award
2018 Purdue University, Seed for Success – for obtaining external sponsored award of \$1 million or more, NIH-R01CA205420
2018 Purdue University, Seed for Success – for obtaining external sponsored award of \$1 million or more, NIH-R01CA226259
2018 American Cancer Society, Research Scholar Awardee, gratefully declined

| | |
|------|--|
| 2018 | Purdue University, Department of Biological Sciences' Team Award |
| 2015 | Purdue University – Favorite Faculty Award Nominee |
| 2013 | Aspen Cancer Conference – Benjamin F. Trump Award for Scientific Research Excellence |
| 2012 | Yale University, Center for RNA Science and Medicine, Poster Winner for Scientific Content |
| 2012 | American Association of Cancer Research, Women in Cancer Research Scholar |
| 2011 | American Cancer Society Postdoctoral Fellowship |
| 2010 | National Research Service Award Postdoctoral Fellowship (F32) |
| 2008 | National Institutes of Health, Graduate Student Research Festival Fellow 2018 |
| 2007 | Emory University Drug Development and Pharmacogenomics Academy Predoctoral Fellowship |
| 2007 | Emory University Fund for International Graduate Research Fellowship |

Society and Professional Memberships – Current and Past

| | |
|--------------|---|
| 2019 – pres. | American Society of Gene and Cell Therapy |
| 2018 – pres. | Oligonucleotide Therapeutics Society |
| 2014 – pres. | RNA society |
| 2014 – pres. | American Society for the Advancement of Science |
| 2014 – pres. | Purdue Center for Cancer Research |
| 2014 – pres. | Purdue Institute for Drug Discovery |
| 2011 – pres. | American Association of Cancer Research |
| 2011 – pres. | American Association of Cancer Research, Women in Cancer Research |
| 2010 – 2013 | New York Academy of Sciences |

Scientific Community Service

Dr. Kasinski serves as referee for many journals in the field of nucleic acids, tumorigenicity, and pharmacogenomics. A partial list of journals includes *EMBO Molecular Medicine*, *Nature Communications*, *Oncogene*, *Nucleic Acids Research*, *Cancer Prevention Research*, *Cancer Research*, *Clinical Cancer Research*, *Scientific Reports*, *Cancer Discovery*, *Chromosoma*, *Cancers*, *Molecular Therapy*, *Molecular Therapy – Nucleic Acids*, *Molecular Cell*, *Biochemistry and Cell Biology*, *Tumor Biology*, *Molecular Therapy*, *Bio-protocols*, *Thompson Reuters - Drug Profiles*, *Toxicological Sciences*, *BMC Cancer* and *Molecular Pharmacology*.

Patent Disclosures

Provisional submitted for the following:

1. Vehicle free delivery of miRNAs: 2016-KASI-67538
2. Ligand ionophore conjugates: 2017-LOW-67710
3. Ligand-targeted delivery for prostate cancer therapy. 2020-KASI-69049
4. Folate-fully-modified-miR-34a as an anti-cancer agent

Full application:

1. Ligand ionophore conjugates: 2016-KASI-67532-02, PCT/US2017/061997, currently licensed to Endocyte

Additional Professional Activities

Academia

- 2022 – pres. Program Leader, Purdue Institute for Cancer Research
- 2021 – pres. Chair of Graduate Program in Biological Sciences
- 2021 – pres. Head of Cancer Research Day Organizing Committee, Purdue Institute for Cancer Research
- 2020 – pres. Member of Purdue Institute for Cancer Research Steering Committee
- 2015 – pres. Co-director Life Sciences Postdoc Initiative, Purdue University
- 2008 – 2009 Teaching Assistant, Emory University
- 2000 – 2009 Research Technician, Emory University

Conference Organization

- 2021 Chair, Purdue Institute for Cancer Research Retreat
- 2016 Session Chair, American Association of Cancer Research, New Orleans, LA
- 2014 Chair, miRNA World, Boston MA

Journal Editor

- 2020 – pres. Associate Editor, *Molecular Carcinogenesis*
- 2013 – pres. Eminent Editor, *Journal of Cytology and Molecular Biology*
- 2011 – 2012 Guest Editor, *DNA and Cell Biology*, special “Epigenetics” issue

Grant Review/Study Sections (total proposals reviewed since arriving at Purdue: 107)

- 2014/01 Clinical and Translational Science Institute of Indiana (5 proposals)
- 2014/01 Medical Research Council of UK (1 proposal)
- 2014/06 Austrian Academy of Sciences (1 proposal)
- 2014/08 Morehouse Tuskegee University/UAB grant review (2 proposals)
- 2015/04 NCI R03/R21 study section, ZCA1 SRB-C M3 (9 proposals)
- 2015/05 NCI R03/R21 study section, ZCA1 SRB-C O1 (9 proposals)
- 2015/11 NCI R03/R21 study section, ZCA1 SRB-1 J1 (7 proposals)
- 2015/08 Worldwide Cancer Research grant review (1 proposal)
- 2016/04 NCI R03/R21 study section, ZCA1 SRB-C M1 (9 proposals)
- 2016/11 NIH/GM/SCORE, study section, ZGM1 RCB-6 SC (6 proposals)
- 2016/12 Florida Department of Health Bankhead-Coley Cancer Research Program, (2 proposals)
- 2017/02 Clinical and Translational Science Institute of Indiana, (5 proposals)
- 2017/05 PCCR American Cancer Society, (1 proposal)
- 2017/06 NCI R03/R21 study section, ZCA1 SRB-5 O1 (6 proposals)
- 2017/12 Florida Department of Health Research Program (1 proposal)
- 2018/05 Purdue University, Robbers Awards (4 proposals)
- 2018/05 Florida Department of Health Research Program (1 proposal)
- 2018/06 NCI R21/R03 FOA study section (8 proposals)
- 2018/06 Purdue Center for Drug Discovery (18 proposals)
- 2018/12 Florida Department of Health Research Program (1 proposal)

| | |
|---------|--|
| 2019/02 | NIH P01 ZCA1 RPRB-F (M1) (request to serve as the primary reviewer of 1 P01, reviewer of 3 projects, and 2 cores, only Assistant Professor on panel) |
| 2019/12 | Florida Department of Health Research Program (3 proposals) |
| 2020/02 | American Cancer Society (1 proposal) |
| 2020/02 | NIH P01 ZCA1 RPRB-L (M1) (request to serve as the primary reviewer of 1 P01, 2 projects, and 1 core) |
| 2020/04 | Pennsylvania Department of Health (1 proposal) |
| 2020/06 | NIH SBIR/STTR Cancer Biotherapeutics Development (9 proposals) |
| 2020/11 | Florida Department of Health Research Program (2 proposals) |
| 2021/06 | NIH SBIR/STTR Cancer Biotherapeutics Development (9 proposals) |
| 2021/11 | Florida Department of Health Research Program (2 proposals) |
| 2022/03 | NIH SBIR/STTR Cancer Biotherapeutics Development |
| 2023/02 | NIH – Nucleic Acid Therapeutics Delivery (NATD) (6 proposals) |

Courses Taught at Purdue

| | |
|--------------|---|
| 2014, 2015 | Biology Honors Course (BIOL 197) – Guest lecture |
| 2015, 2016 | Signal Transduction (BCHM 610) – Guest Lecture |
| 2015, 2016 | Regulation of Gene Expression (BCHM) – Guest lecture |
| 2015 – 2017 | Undergraduate Research Day (BIOL293) – Guest lecture |
| 2015 – 2016 | Current Topics in Noncoding RNA (BIOL 495) – 15 lectures/semester |
| 2015 – 2017 | Epigenetics in Human Disease (BIOL 595) – 30 lectures/semester |
| 2017 – pres. | Cell Structure and Function (BIOL 231) – 41 lectures/semester |

Publication Information

Original Research Peer Reviewed Journal Articles

1. Nellis, M.M., Doering, C.B., **Kasinski, A.** and Danner, D.J. (2002) *Insulin increases branched chain α -ketoacid dehydrogenase kinase expression in Clone 9 rat cells*. Am J. Physiol. 238: E853-E860.
2. Nellis, M.M., **Kasinski, A.**, Carlson, M., Allen, R., Schaefer, A.M., Schwartz, E.M., Danner, D.J. (2003) *Relationship of causative genetic mutations in maple syrup urine disease with their clinical expression*. Mol. Genet. Metab. 80: 189-95
3. **Kasinski, A.**, Doering, C.B. and Danner, D.J. (2004) *Leucine toxicity in a neuronal cell model with inhibited branched chain amino acid catabolism*. Molecular Brain Research 122: 180-7.
4. **Kasinski, A.L.**, Du, Y., Thomas, S., Zhao, J., Sun, S.Y., Khuri, F.R., Wang, C.Y., Shoji, M., Sun, A., Snyder, J., Liotta, D., Fu, H. (2008) *Inhibition of IKK-NF- κ B signaling pathway by EF24, a novel monoketone analogue of curcumin*. Molecular Pharmacology Sep; 74(3):654-61
5. **Kasinski, A.L.**, Slack, F.J. (2012) *miRNA-34 prevents cancer initiation and progression in a therapeutically resistant Kras and p53-induced mouse model of lung adenocarcinoma*. Cancer Research, Sept; 72, 5576-5587

In November of 2012, Commentary and News Report on Cancer Research publication from Yale Newsroom <https://tinyurl.com/ycf37u7n>.

6. Puckett, M.C., Goldman, E.H., Cockrell, L.M., Huang, B., **Kasinski, A.L.**, Du, Y., Wang, C., Lin, A., Ichijo, H., Khuri, F.R., and Fu, H. (2013) *Integration of the Apoptosis signal-regulating kinase 1- mediated stress signaling with the Akt/PKB-IkB kinase cascade*. Molecular and Cellular Biology, Jun;33(11):2252-9
7. **Kasinski, A.L.**, Slack, F.J. (2013) *Generation of mouse lung epithelial cells*. Bio-Protocols. August 2013 * corresponding author. Featured protocol for both Cancer and Cell Biology.
8. **Kasinski, A.L.**, Dong, X., Khuri, F.R., Boss, J., Fu, H. (2014) *Transcriptional regulation of YWHAZ, the gene encoding 14-3-3 zeta* PLoS-ONE 9(4) e93480
9. **Kasinski, A.L.**, Kelner, K., Stahlhut, C., Orellana, E.A., Zhao, J., Shimer, E., Dysart, S., Bader, A.G., Slack, F.J. (2015) *A combinatorial microRNA therapeutic approach to suppressing Kras;p53 mutant non-small cell lung cancer*. Oncogene 2015 Jul;34(27):3547-55

In September of 2014, Commentary and News Report on Oncogene publication from Beth Israel Deaconess Medical Center, Harvard University was published by >5 independent outlets. Additional press releases and reviews covering this work increased the altmetric score of this publication to 56.

Highlighted in Eureka Alter: AAAS: <https://tinyurl.com/y746wqd9>

Highlighted in Science Daily: <https://tinyurl.com/y92ckh9s>

Highlighted in RT Magazine: <https://tinyurl.com/y9c9peq2>

Highlighted in Medical Express: <https://tinyurl.com/ybpps2j>

Highlighted in MDLinx: <https://tinyurl.com/y8oldxkb>

And others

10. Orellana, E.A., and **Kasinski A.L.** (2016) *Sulforhodamine B (SRB) Assay*. Bio-protocol Col 6, Iss 21 11/5/2016
11. Gilbert-Ross, M., Konen, j., Koo, J., Shupe, J., Robinson, B., Wiles, W., Huang, C., Martin, D., Behera, M., Smith, G., Hill, C., Rossi, M., Sica, G., Rupji, M., Chen, Z., Kowalski, J., **Kasinski, A.L.**, Samalingah, S., Fu, H., Khuri, F., Zhou, W., Marcus, A. (2017) *Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma*. Journal of Clinical Investigation Insight. 2017 Mar 9;2(5)e90487
12. Orellana, E.A., Tenneti, S., Rangasamy, R., Lyle, L.T., Low, P.S., **Kasinski, A.L.** (2017) *FolamiRs: Ligand-targeted, vehicle-free microRNA replacement therapy*. Science Translational Medicine. 2017 Aug 2;9(401)

In August of 2017, Commentary and News Report on Science Translational Medicine publication from Purdue Newsroom was published by 4 independent outlets. Additional

press releases and reviews covering this work increased the altmetric score of this publication to 50.

Highlighted in Purdue News: <https://tinyurl.com/ybcjuj9t>

Highlighted by Oligonucleotide Therapeutics Society: <https://tinyurl.com/yc3m9een>

Highlighted in Genetic Eng. and Biotechnology News: <https://tinyurl.com/ybqjyx26>

Highlighted in Medical Express: <https://tinyurl.com/ydbt86n7>

Reviewed in a local magazine in Ecuador: <https://tinyurl.com/ybc3gyou>

Reviewed in Oncotarget: <https://tinyurl.com/ybr58kn3>

And others

13. Zhou, W., Pal, A.S., Hus, A.Y., Gurol T., Zhu, X., Wirbisky-Hershberger, S.E., Freeman, J.L., **Kasinski, A.L.**, Deng, Q. (2018) *MicroRNA-223 suppresses the canonical NF- κ B pathway in basal keratinocytes to dampen neutrophilic inflammation*. Cell Reports 2018 Feb 13;22(7):1810-1823

In February of 2018, Commentary and News Report on Cell Reports publication from Purdue Newsroom was published by 2 independent outlets.

Highlighted in Purdue News: <https://tinyurl.com/yc8yy5nf>

Highlighted in Medical Express: <https://tinyurl.com/y86shf5z>

14. Rangasamy, L., Chelvam, V., Kanduluru, A.K., Srinivasarao, M., Bandara, A.N., You, F., Orellana, E., **Kasinski, A.L.**, Low, P.S. (2018) *New mechanism for release of endosomal contents: osmotic lysis via nigericin-mediated K⁺/H⁺ exchange*. Bioconjugate Chemistry 2018 Feb 15
15. Orellana, E.A., Abdelaal, A.H., Rangasamy, R., Tenneti, S., Myoung, S., Low, P.S., **Kasinski, A.L.** (2019) *Enhancing microRNA activity through increased endosomal release mediated by nigericin*. Molecular Therapy: Nucleic Acids, Vol 16, 505-518
16. Orellana E.A., Li, C., Lisevick, A., and **Kasinski, A.L.** (2019) *Identification and validation of microRNAs that synergize with miR-34a – a basis for combinatorial microRNA therapeutics*. Cell Cycle, 2019 Aug;18(15):1798-1811
17. Pal, A.S., Bains, M., Agredo, A., and **Kasinski A.L.** (2020) *Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer*. Biochemical Pharmacology 2020 Jul 16:114154
18. Elshafie, N., do Nascimento, N., Lichti, N., **Kasinski A.L.**, Childress, M., Santos, A. (2021) *MicroRNA biomarkers in canine diffuse large B-cell lymphoma*. Veterinary Pathology 2021 Jan;58(1):34-41
19. Hasan, H., Sohal, I.S., Soto-Vargas, Z., Byappanhalli, A.M., Humphrey, S.E., Kubo, H., Kitdumrongthum, S., Copeland, S., Tian, F., Chairoungdua, A., and **Kasinski, A.L.** (2022)

Extracellular vesicles released by non-small cell lung cancer cells drives invasion and permeability in non-tumorigenic lung epithelial cell. Scientific Reports 2022 12, 972 (2022)

20. Pal, A.S., Agredo, A., Lanman, N.A., Son, J., Sohal, I.S., Bains, M., Li, C., Clingerman, J., Gates, K., **Kasinski, A.L. (2022)** *Loss of KMT5C promotes EGFR inhibitor resistance in NSCLC via LINC01510-mediated upregulation of MET.* Cancer Research Apr15;82(8):1534-1547

In April of 2022, Commentary and News Report on Cancer Research publication from Purdue Newsroom was published by multiple news outlets. Additional ten press releases and reviews covering this work increased the altmetric score of this publication to 93, which falls into the top 5% of all output scores by Altmetric and is within the top 96 percentile of same age articles from Cancer Research.

Highlighted in Purdue News: <https://tinyurl.com/2p8dn9sm>

21. Pal, A.S., Agredo, A., **Kasinski, A.L. (2022)** *In-cell western protocol for semi-high throughput screening of single clones.* BioProtocol, vol 12, iss 16. Doi: 10.21769/BioProtoc.4489
22. Abdelaal, A.M., Sohal, I.S., Iyers, S., Sudarshan, K., Lanman, N.A., Kothandaraman, H., Low, P.S., **Kasinski, A.L. (2023)** *A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.* Cancer Research (under Review)

Preprint Articles

1. Orellana, E.A., Rangasamy, L., Tenneti, S., Abdelaal, A.M., Low, P.S., **Kasinski, A.L. (2018)** *Enhancing microRNA activity through increased endosomal release mediated by nigericin.* July 2018 bioRxiv doi: <https://doi.org/10.1101/367672>
2. Pal, A.S., Agredo, A.M., Lanman, N.A., Clingerman, J., Gates, K., **Kasinski, A.L. (2020)** *Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510.* March 2020 bioRxiv doi: <https://doi.org/10.1101/2020.03.17.995951>

Invited Reviews

1. **Kasinski, A.L., Slack, F.J. (2010)** *Potential microRNA therapies targeting Ras, NF- κ B and p53 signaling.* Current Opinion in Molecular Therapeutics, Apr; 12(2):147-57
2. **Kasinski, A.L., Fu, H. (2011)** *14-3-3 zeta.* UCSD-Nature Molecule Pages. (doi:10.1038/mp.a000060.01)
3. Kim, M., **Kasinski, A.L., Slack, F.J. (2011)** *MicroRNA therapeutics in pre-clinical cancer models.* Lancet Oncology, Apr;12(4):319-321
4. **Kasinski, A.L., Slack, F.J. (2011)** *Therapeutic microRNAs en route to the clinic: progress in*

validating and targeting miRNAs for cancer therapy. Nature Reviews Cancer, Nov 24; 11(12):849-64

5. **Kasinski, A.L.**, Slack, F.J. (2012) *Arresting the culprit: targeted antagomir delivery to sequester oncogenic miR-221 in HCC*. Molecular Therapy – Nucleic Acids, March; 1(3):12
6. ***Kasinski, A.L.**, *Slack, F.J. (2013) *Small RNAs deliver a blow to ovarian cancer*. Cancer Discovery, November 2013 3;1220 * co-corresponding authors
7. Adams, B.A., ***Kasinski, A.L.**, Slack, F.J. (2014) *Aberrant regulation and function of microRNAs in cancer*. Current Biology Vol24;16:R762-R776 *co-first authors
8. Zeiger, Z., Gollapudi, B., Aardema, M., Auerbach, S., Boverhof, D., Custer, L., Dedon, P., Honma, M., Ishida, S., **Kasinski, A.L.**, Kim, J.H., Manjanatha, M., Marlowe, J., Pfuhrer, S., Pogribny, I., Slikker, W., Stankowski, L.F., Tanir, J.Y., Tice, R., van Benthem, J., White, P., Witt, K.L., Thybaud, V. (2015) *Opportunities to integrate new approaches in genetic toxicology: An ILSI-HEIS workshop report*. Environmental Molecular Mutagenesis 2015 Apr;56(3):277-85
9. Humphrey, S. and **Kasinski, A.L.** (2015) *RNA guided CRISPR-Cas Technologies for Genome Scale Investigation of Disease Processes*. Journal of Hematology and Oncology. 2015 April 2;8(1):31.
10. Orellana E.A., and **Kasinski, A.L.** (2015) *MicroRNAs in cancer: A historical perspective on the path from discovery to therapy*. Cancers 7(3), 1388-1405
11. Pal, A.S., and **Kasinski, A.L.** (2017) *Animal models to study microRNA function*. Advances in Cancer Research 135:53-118
12. Orellana, E.A., **Kasinski, A.L.** (2017) *No vehicle, no problem*. Oncotarget. 2017 Oct27;8(57):96470-96471
13. **Kasinski, A.L.** (2019) *Combatting PDAC with two tumor-targeting small RNAs*. Oncotarget 2019 Oct 15;10(57):5892-5893 <http://doi.org/10.1080/15384101.2019.1634956>
14. Li, C., and **Kasinski, A.L.** (2020) *In vivo cancer-based functional genomics*. Trends in Cancer 2020, Aug 19:S2405-8033(20)31212-0
23. Li, W., Wang, Y., Liu, R., **Kasinski, A.L.**, Shen, H., Slack, F.J., and Tang, D.G. (2021) *MicroRNA-34a (miR-34a): Potent Tumor Suppressor, Cancer Stem Cell Inhibitor and Potential Anti-Cancer Therapeutic*, Frontiers in Cell and Developmental Biology, 9:640587.
24. Abdelaal, A.M., and **Kasinski, A.L.** (2021) *Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological disease*. Nucleic Acid Research, Cancer, Jul 20;3(3):zcab030

25. Sohal, I.S. and **Kasinski, A.L. (2022)** *Extracellular vesicle biogenesis in cancer*. *Frontiers in Endocrinology*. (Under Review)
26. Agredo A.M. and **Kasinski, A.L. (2022)** *Histone 4 lysine 20 trimethylation: A key epigenetic regulator in chromatin structure and disease* (Under Review)

Peer Reviewed Books and Chapters

1. Danner, D.J., Muller, E.A., **Kasinski, A. (2003)** *The complexity of single gene disorders: Lessons from maple syrup urine disease and thiamin responsiveness. Thiamine: catalytic mechanisms and role in normal and disease states*. Ed by M.S. Patel and F. Jordan, Academic Press (2004).
2. Park, H.R., Cockrell, L.M., Du, Y., **Kasinski, A.**, Havel, J., Zhao, J., Reyes-Turcu, F., Wilkinson, K., Fu, H. **(2008)** *Methods for Protein-Protein Interactions*, *Molecular Biomethods Handbook* 2nd Edition.
3. Myoung, S., and **Kasinski, A.L. (2019)** *MicroRNAs in Diseases and Disorders – Emerging Therapeutic Targets. Chapter 22: Strategies for safe and targeted delivery of microRNA therapeutics*. Royal Society of Chemistry.

Abstracts submitted by Dr. Kasinski since arriving at Purdue (International excluding abstracts internally at Purdue)

1. **Kasinski, A.L.**, Bader, A.G., and Slack, F.J. *miR-34 and let-7 prevent endogenous lung tumor progression in the therapeutically resistant $Kras^{G12D/+};Trp53$ mouse model*. International RNA Society Annual Meeting, Quebec, Canada. June 2014
2. **Kasinski, A.L.** *A combinatorial microRNA therapeutics approach to eradicating NSCLC*. 3rd Annual Summit on Thoracic Malignancies and Head and Neck Cancer, Puerto Rico December 2015 (**oral presentation**)
3. **Kasinski, A.L.** *A combinatorial microRNA therapeutics approach to suppressing cancer growth*. Experimental Biology, ASPET, San Diego, CA, April 2016 (**oral presentation**)
4. **Kasinski, A.L.** *A macro role for microRNAs: Enhancing the clinical utility of microRNAs*. American Association for Cancer Research, New Orleans, LA, April 2016 (**oral presentation**)
5. **Kasinski, A.L.** *FolamiRs: Vehicle-free delivery of therapeutic microRNAs*. 6th International Symposium on Folate Receptors and Transporters, Breckenridge CO, September 2016 (**oral presentation**)
6. **Kasinski, A.L.**, *Ligand-targeted, vehicle-free microRNA replacement*. The 22nd Annual Meeting of the RNA Society, Prague, Czech Republic, May 2017 (**oral presentation**)
7. **Kasinski, A.L.**, *Ligand-targeted, vehicle-free microRNA replacement*. The Long and Short of Non-coding RNA, Crete, Greece, June 2017 (**oral presentation**)
8. **Kasinski, A.L.**, *Vehicle-free delivery of therapeutic RNAs*. RNA Therapeutics: Basepairs to Bedside, University of Massachusetts, Worcester, MA, June 2018 (**oral presentation**)
9. **Kasinski, A.L.**, *Ligand-mediated, vehicle-free delivery of small RNAs*. Oligonucleotide Therapeutics Society, Seattle, Washington, October 2018 (**oral presentation**)

Invited Lectures

1. National and International Meetings (22, international locations underlined)

1. 8th Annual miRNA in Human Disease & Development, Cambridge Healthtech, March 2012
2. ILSI Health and Environmental Science Institute, Silver Springs MD, April 2012
3. The 4th Japanese Assoc. for RNAi International Symposium, Hiroshima, Japan, August 2012
4. Aspen Cancer Conference, Aspen, Co, July 2013
5. MiRNA World 2014, Boston, MA, October 2014
6. 2nd Annual Summit on Practical and Emerging Approaches to Lung Cancer, Dallas TX, December 2014
7. Association for Research in Otolaryngology, Baltimore, MD, February 2015
8. MicroRNAs as Biomarkers and Diagnostics, Cambridge, MA, March 2015
9. 3rd Annual Summit on Thoracic Malignancies and Head & Neck Cancers, San Juan, Puerto Rico, Dec 2015
10. ASPET, Experimental Biology, San Diego, CA, April 2016
11. American Association of Cancer Research, New Orleans, LA, April 2016
12. 6th International Folate Receptors Symposium, Breckenridge, CO, September 2016
13. RNA as a Guide, Barbados, April 2017
14. Non-coding RNA Symposium, University of Alabama, Birmingham, November 2017
15. The RNA Summit, Boston, MA, November 2017
16. FASEB SRC: Post-transcriptional control of gene expression, Scottsdale AZ, June 2018
17. 5th Annual International Conference on Drug Discovery, Development and Lead Optimization, Boston MA, November 2019
18. mRNA Untranslated Regions in Gene Regulation, Development, and Disease, Barbados, January 2020
19. Current Innovations & the Future of Therapeutic Development. Vellore Institute of Technology, India, June 2020
20. microRNA symposium, University of Illinois at Chicago, September 2021
21. RNA-mediated silencing, Barbados, January 2022, Canceled due to Covid
22. American Association for Cancer Research (AACR), Plenary Talk April 2023, Orlando Florida
23. RNA-mediated silencing, Barbados, April 2023
24. Folate Receptor Meeting, New York, October 2023

2. Regional Meetings and Workshops (11)

1. NIH Lung SPORE Workshop, National Cancer Institute, Rockville, MD, July 2013
2. Purdue Center's Directory Advisory Board luncheon at the Cincinnati Woman's Club, Cincinnati, OH, September 12, 2016
3. Science on Tap at Lafayette Brew Pub, May 2017
4. Purdue Center for Cancer Research, CIS series, West Lafayette IN, March 2017
5. Keynote, NSF-Funded Science Outreach, Carnegie Museum, Crawfordsville, IN, April 2018
6. Midwest Chromatin and Epigenetics Meeting, Purdue University, West Lafayette, IN, June 2018

7. Biden Cancer Summit, Purdue 150th Anniversary Celebration, West Lafayette, IN, September 2018
8. Purdue Center for Cancer Research, CIS series, West Lafayette IN, February 2019
9. Keynote, Purdue Relay for Life's Hope Gala, West Lafayette, IN, February 2019
10. Keynote, Bindley Biosciences Graduate Research Symposium, West Lafayette, IN, April 2020 (canceled due to Coronavirus)
11. Women in Science Program, Purdue University, West Lafayette, IN, November 2020

3. Universities and Other Institutions (18, not including multiple talks at Purdue, international locations underlined)

1. Thoracic Oncology Board, Emory University, Atlanta GA, May 2012
2. Department of Biology, Purdue University, West Lafayette IN, December 2012
3. Departments of Hematology and Medical Oncology, and Radiation Oncology, Emory University, Atlanta, Ga, March 2013
4. Department of Clinical Cancer Prevention, MD Anderson Cancer Center, Houston Tx, March 2013
5. Department of Molecular Pathology, MD Anderson Cancer Center, Houston Tx, April 2013
6. Purdue University, Calumet Campus, Department of Biological Sciences, Hammond, IN, August 2014
7. Indiana University, Department of Biochemistry and Molecular Biology, March 2015
8. Universidad de Antioquia, Medellin, Columbia, November 2015
9. Indiana University Purdue University Indianapolis (IUPUI), Department of Biology, Indianapolis, January 2017
10. Roswell Park Cancer Institute, The University of Buffalo, July 2017
11. University of Montreal, February 2018
12. Keynote Speaker, 19th Annual Fellow's Colloquium, National Cancer Institute, Bethesda, MA, February 2019
13. Mahidol University, Bangkok Thailand, March 2019
14. University of North Carolina Chapel Hill, Keynote Speaker, December 2019
15. Roswell Park Cancer Institute, The University of Buffalo, January 2020
16. Manchester University, November 2020
17. University of Illinois – Urbana Champaign, Department of Cell and Developmental Biology, March 2022
18. Harvard Medical School, Initiative for RNA medicine, October 2022

4. Invited Webinar Lectures (4)

1. The Scientist, *The success and tribulations of using non-coding RNAs as therapeutics*. July 2015
2. The Scientist, *FolamiRs: Vehicle-free delivery of therapeutic microRNAs*. October 2016
3. Oligonucleotide Therapeutics Society. *Design of microRNA therapeutics*. March 2019
4. The Scientist, *To the tumor and beyond: a tale of a holistic microRNA delivery vehicle*, February 2022

Funding (total to date - \$5,409,868, not including trainee funding)

On-going

Lung Cancer Research Program, Idea Award (**\$530,488**)

Department of Defense

(PI: Kasinski)

09/30/22 – 08/31/24

“Ligand-Mediated Detection and Treatment of Metastatic Lung Cancer, Including Tumors Localized in The Central Nervous System”

R01 CA205420 (**\$1,757,221**)

NIH

(PI: Kasinski)

09/01/17 – 08/31/23

“Enhancing miRNA therapeutics through combinatorial targeting and vehicle-free delivery”

The overall goal of the project is to identify miRNAs that synergize with miR-34a and to evaluate their efficacy in vivo through a novel ligand-mediated delivery platform based on the folate ligand.

R01 CA226259 (**\$1,908,079**)

NIH

(PI: Kasinski)

04/01/18 – 03/31/24

“Ligand-mediated delivery of small RNAs”

The overall goal of the project is to generate and test folate-nigericin-miRNA conjugates to facilitate endosomal release of miRNAs.

Notable external funding of trainees in the Kasinski Laboratory

NIH-F31 (~**\$150,000**)

(PI: graduate student Zuliada Soto)

08/01/21 – 07/31/23

“Mechanisms of secretion and uptake of small extracellular vesicles in non-small cell lung cancer”

Department of Defense (**\$465,000**) (PI: postdoc Iqbal Shoaib)

04/01/21 – 03/31/23

“Ligand-targeted miRNA delivery for prostate cancer therapy”